| Literature DB >> 29385063 |
Shu-Rong Chen1, Shih-Wei Wang2,3, Chien-Jung Su4, Hao-Chun Hu5, Yu-Liang Yang6,7, Chi-Ting Hsieh8, Chia-Chi Peng9, Fang-Rong Chang10,11, Yuan-Bin Cheng12,13.
Abstract
Three new compounds, tuberazines A-C (1-3), and eleven known compounds (4-14) were obtained from theEntities:
Keywords: Palythoa tuberculosa; alkaloids; anti-lymphangiogenesis; pyrazines
Mesh:
Substances:
Year: 2018 PMID: 29385063 PMCID: PMC5852475 DOI: 10.3390/md16020047
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1−14.
1H NMR Data of 1–3 in CD3OD .
| NO. | 1 | 2 | 3 |
|---|---|---|---|
| 1 | 4.30, ddd (11.7, 5.7, 2.9) | 4.29, ddd (11.6, 5.6, 3.5) | 4.30, ddd (11.9, 5.6, 4.2) |
| 3.91, ddd (11.7, 10.5, 3.5) | 3.93, ddd (11.6, 10.2, 3.5) | 3.93, ddd (11.9, 9.8, 4.2) | |
| 2 | 3.15, ddd (16.8, 10.5, 5.6) | 3.12, ddd (16.8, 10.2, 5.6) | 3.15, ddd (16.8, 9.8, 5.6) |
| 2.84, dt (16.8, 3.5) | 2.84, dt (16.8, 3.5) | 2.83, m | |
| 6 | 4.74, m | 4.84, d (16.1) | 2.86, m |
| - | 4.76, d (16.1) | - | |
| 7 | - | - | 3.91, ddd (11.9, 9.8, 4.2) |
| 8 | 4.30, ddd (11.7, 5.6, 3.5) | 3.93, ddd (11.2, 6.3, 3.5) | - |
| 3.91, ddd (11.7, 10.5, 3.5) | - | - | |
| 9 | 3.15, ddd (16.8, 10.5, 5.6) | 2.89, m | 4.85, d (14.0) |
| 2.84, dt (16.8, 3.5) | - | 4.76, d (14.0) | |
| 13 | 4.74, m | 4.73, m | 4.71, m |
| 15 | 4.06, dd (11.8, 2.7) | 4.08, dd (11.9, 2.8) | 4.06, dd (11.9, 2.8) |
| 3.98, dd (11.8, 5.7) | 4.01, dd (11.9, 5.6) | 3.99, dd (11.9, 5.6) | |
| 16 | 4.06, dd (11.8, 2.7) | 3.74, dd (11.2, 3.5) | 3.73, dd (11.9, 3.8) |
| 3.98, dd (11.8, 5.7) | 3.69, dd (11.2, 6.3) | 3.69, dd (11.9, 6.3) |
Data were measured at 700 MHz; Chemical shifts are in ppm. J values (Hz) in parentheses.
13C NMR Data of 1–3 in CD3OD .
| NO. | 1 | 2 | 3 |
|---|---|---|---|
| 1 | 64.5, CH2 | 64.4, CH2 | 64.4, CH2 |
| 2 | 32.4, CH2 | 33.2, CH2 | 33.2, CH2 |
| 3 | 149.5, C | 149.2, C | 149.6, C |
| 5 | 149.9, C | 148.4, C | 149.5, C |
| 6 | 79.8, CH | 69.6, CH2 | 33.5, CH2 |
| 7 | - | - | 77.1, CH |
| 8 | 64.5, CH2 | 77.2, CH | - |
| 9 | 32.4, CH2 | 33.5, CH2 | 69.6, CH2 |
| 10 | 149.5, C | 149.4, C | 148.4, C |
| 12 | 149.9, C | 150.3, C | 149.9, C |
| 13 | 79.8, CH | 79.7, CH | 79.7, CH |
| 15 | 64.7, CH2 | 64.6, CH2 | 64.5, CH2 |
| 16 | 64.7, CH2 | 65.5, CH2 | 65.5, CH2 |
Data were measured at 175 MHz; Chemical shifts are in ppm.
Figure 2COSY (bold bond), 1H-13C HMBC (blue arrow), and 1H-15N HMBC (red arrow) correlations of 1–3.
Figure 3Calculated (yellow and gray lines) and experimental ECD (green line) spectra of 1.
Figure 4Effects of tuberazines A–C (1–3) on cell growth of human LECs. Cells were treated with tuberazines A–C (1–3) and rapamycin (5 μg/mL) for 48 h, and anti-lymphangiogeneic activity was determined using cell growth assay. Data are expressed as the mean ± SEM of five independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control group.
Figure 5Effects of tuberazines A–C (1–3) on tube formation and cytotoxicity of human LECs. (A) Cells were plated on Matrigel-coated plates in tuberazines A–C (1–3) (50 μg/mL) for 8 h, and tubular morphogenesis was recorded by the inverted phase contrast microscope. Images were representative of results from five separate experiments. Tube formation was quantified by measuring the length of tubes with the use of Image-J. (B) Cells were treated with tuberazines A–C (1–3) (50 μg/mL) for 24 h, then the cytotoxicity was determined using LDH assay. Data are expressed as the mean ± SEM of at least three independent experiments. ** p < 0.01, *** p < 0.001 compared with the control group.